Artificial Intelligence Accelerates Discovery of Novel Peptide, Offering Precision Approach to Weight Management Without Prevalent Side Effects

Pioneering research leveraging artificial intelligence has led Stanford Medicine scientists to identify a naturally occurring peptide that demonstrates significant potential in suppressing appetite and reducing body weight, circumventing the gastrointestinal and muscle-related adverse effects commonly associated with existing GLP-1 receptor agonist therapies. This breakthrough represents a substantial advance in the quest for more refined and tolerable treatments for obesity, a global health challenge impacting millions.

The worldwide prevalence of obesity has reached epidemic proportions, presenting a formidable public health crisis that strains healthcare systems and diminishes quality of life for individuals. Characterized by excessive body fat accumulation, obesity is a multifactorial condition linked to a cascade of severe health complications, including type 2 diabetes, cardiovascular disease, certain cancers, and musculoskeletal disorders. Despite extensive research, effective and universally well-tolerated pharmacotherapies have remained elusive. Current treatments, such as glucagon-like peptide-1 (GLP-1) receptor agonists like semaglutide, have revolutionized weight management with their impressive efficacy in promoting satiety and facilitating weight loss. However, their widespread action across various organ systems frequently results in adverse effects, notably nausea, vomiting, constipation, and, concerningly, a significant reduction in lean muscle mass alongside fat loss. These limitations underscore an urgent unmet medical need for more targeted interventions that offer comparable efficacy with an improved safety profile.

Against this backdrop, the discovery of BRP (BRINP2-related-peptide) emerges as a potentially transformative development. Unlike semaglutide, which acts broadly on GLP-1 receptors distributed throughout the brain, gut, pancreas, and other tissues, BRP operates via a distinct, albeit related, metabolic pathway. Its mechanism involves the activation of a separate, more specific group of neurons primarily within the hypothalamus. This critical distinction holds profound implications for therapeutic precision. The hypothalamus, a compact but profoundly influential region deep within the brain, serves as the central command center for vital physiological functions, including hunger, thermoregulation, hormone activity, and energy expenditure. By selectively modulating hypothalamic circuits, BRP exhibits the promise of influencing appetite and metabolic regulation with minimal off-target effects elsewhere in the body, thereby offering a more refined approach to weight control. Dr. Katrin Svensson, an assistant professor of pathology and senior author of the pivotal research published in Nature, has been instrumental in this endeavor and has co-founded a company poised to advance BRP into human clinical trials in the near future.

The journey to identifying BRP was fundamentally accelerated and enabled by the strategic application of artificial intelligence. Traditional biochemical methods for discovering novel bioactive peptides are notoriously laborious and resource-intensive. Proteins known as prohormones are inactive precursor molecules that must be enzymatically cleaved into smaller peptide fragments before they can exert their biological functions, often acting as hormones that regulate complex processes like metabolism and appetite. The challenge lies in the sheer combinatorial complexity: a single prohormone can yield numerous distinct peptides, only a minuscule fraction of which possess genuine biological activity. Isolating and identifying these critical signaling molecules from a vast sea of inert fragments generated during normal protein processing and degradation typically involves mass spectrometry, a technique that can produce overwhelming datasets requiring arduous manual sifting through hundreds of thousands of molecular entities to pinpoint a few with meaningful effects.

Recognizing these inherent limitations, the research team, led by Dr. Svensson and senior research scientist Dr. Laetitia Coassolo, leveraged computational power to streamline the discovery process. Their focus centered on prohormone convertase 1/3 (PC1/3), an enzyme known to cleave prohormones at specific amino acid sequences and notably implicated in human obesity. Significantly, GLP-1, the very peptide mimicked by semaglutide, is a product of this same enzyme. This connection provided a strong rationale: if PC1/3 generates a key appetite regulator like GLP-1, it likely produces other undiscovered peptides with similar influence over energy balance and satiety.

To systematically search for these hidden metabolic signals, the researchers developed a sophisticated computer algorithm termed "Peptide Predictor." This innovative program was designed to bypass the traditional, time-consuming laboratory extraction of proteins and peptides. Instead, it computationally scanned all 20,000 human protein-coding genes for characteristic cleavage sites recognized by prohormone convertases. The search was then progressively refined by filtering for genes that produce proteins secreted outside the cell—a common characteristic of peptide hormones—and further narrowed to those containing at least four potential cleavage sites. This methodical computational winnowing process dramatically reduced the candidate pool to a more manageable set of 373 prohormones, a critical step that Dr. Svensson emphasized as "absolutely key to our findings."

From these 373 prohormones, Peptide Predictor estimated the potential generation of 2,683 distinct peptides by prohormone convertase 1/3. Dr. Coassolo and Dr. Svensson then strategically focused on sequences most likely to exert an effect within the brain, ultimately selecting 100 peptides, including GLP-1, for in vitro functional testing. This rigorous screening involved assessing their ability to stimulate neuron-like cells cultured in the laboratory. As anticipated, GLP-1 robustly activated these neuronal cells, increasing their activity by threefold compared to untreated control cells. However, one remarkably small peptide, composed of only 12 amino acids, elicited an even more profound response, elevating neuronal activity tenfold above baseline. This potent peptide was subsequently named BRP, derived from its parent prohormone, BPM/retinoic acid inducible neural specific 2, or BRINP2. The sheer potency of BRP, despite its diminutive size relative to most full-sized proteins, was an early indicator of its significant biological potential.

The promising in vitro findings were swiftly followed by comprehensive in vivo studies designed to evaluate BRP’s efficacy and safety in animal models. The researchers administered intramuscular injections of BRP to both lean mice and minipigs—the latter chosen for their metabolic and eating patterns that more closely recapitulate human physiology. A single injection given prior to feeding led to a remarkable reduction in food intake, by as much as 50%, within the subsequent hour in both species. Extending these investigations, obese mice received daily BRP injections over a 14-day period. The results were compelling: treated animals experienced an average weight loss of 3 grams, with the overwhelming majority of this reduction attributed to body fat. In stark contrast, mice in the control group gained approximately 3 grams over the identical timeframe. Beyond weight reduction, the BRP-treated mice also demonstrated significant improvements in glucose and insulin tolerance, critical markers reflecting the body’s efficiency in regulating blood sugar and responding to insulin, the hormone vital for glucose uptake by cells.

Perhaps one of the most compelling aspects of BRP’s profile in these preclinical studies was the conspicuous absence of the common adverse effects associated with existing weight loss medications. Comprehensive behavioral assessments revealed no meaningful differences between BRP-treated and untreated animals in parameters such as general movement, water consumption, anxiety-like behaviors, or fecal production. The lack of change in fecal output was particularly noteworthy, given that semaglutide frequently causes gastrointestinal issues, including constipation, by slowing digestive transit. Crucially, the researchers observed no signs of nausea-related responses or the significant muscle loss that has been a concern with some current weight management therapies. Further mechanistic investigations, analyzing brain activity and overall body function, unequivocally indicated that BRP modulates appetite and metabolism through distinct pathways compared to those activated by GLP-1 or semaglutide. These findings strongly suggest that BRP could offer a more focused biological route to appetite suppression, albeit these results are presently confined to animal models and require validation in human subjects.

While the initial findings for BRP are highly encouraging, several critical questions must be addressed before its potential can be fully realized in human therapeutics. A primary objective for the research team is the precise identification of the cell-surface receptors to which BRP binds. Understanding these molecular docking stations is paramount for elucidating the exact cascade of events that BRP initiates to influence appetite and metabolism. Mapping the full sequence of downstream signaling pathways triggered by BRP binding is another crucial area of ongoing investigation. Furthermore, a significant challenge inherent to small peptides like BRP is their typically rapid degradation within the body, which can severely limit their duration of action. The researchers are actively exploring strategies to enhance BRP’s stability and extend its half-life, a necessary step to enable a practical and convenient administration schedule should it prove effective in humans.

Despite these remaining hurdles, the enthusiasm surrounding BRP is palpable. As Dr. Svensson articulated, "The lack of effective drugs to treat obesity in humans has been a problem for decades. Nothing we’ve tested before has compared to semaglutide’s ability to decrease appetite and body weight. We are very eager to learn if it is safe and effective in humans." The planned progression to clinical trials represents a pivotal juncture in evaluating BRP’s translational potential. This collaborative research effort, involving contributions from the University of California, Berkeley, the University of Minnesota, and the University of British Columbia, underscores the multidisciplinary nature of cutting-edge scientific discovery. The project also received substantial funding from diverse sources, including the National Institutes of Health, the SPARK Translational Research Program at Stanford, Stanford Bio-X, the Stanford Maternal and Child Health Research Institute, the American Heart Association, a Stanford Medicine Dean’s Fellowship Award, the Carlsberg Foundation, and the Wu Tsai Human Performance Alliance, reflecting the broad recognition of its significance.

This groundbreaking work not only introduces a promising new candidate for obesity treatment but also powerfully illustrates the burgeoning role of artificial intelligence in accelerating fundamental biological discovery and drug development. By harnessing AI to navigate the vast complexities of the human proteome, scientists can now more efficiently uncover novel therapeutic targets and agents, paving the way for a new era of precision medicine in metabolic health. Should BRP successfully navigate the rigorous phases of human clinical trials, it could herald a significant paradigm shift, offering a highly effective, more tolerable, and targeted option for individuals struggling with obesity and its associated health burdens.